On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for relapsed/refractory multiple myeloma.
Xavier Leleu, MD, PhD
Advertisement
Xavier Leleu, MD, PhD, is the head of the Department of Haematology and the Myeloma Clinic at Hôpital La Mileterie, in Poitiers, France.
Articles by Xavier Leleu, MD, PhD
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (RRMM).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
3
New Biomarkers, Drug Targets Identified for Colorectal Cancer
4
Colorblind Devices, Longer-Wavelength Lasers Offer Safer Options for Darker Skin Tones: Ariella Kauvar, MD
5
